You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Details for Patent: 8,541,575


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 8,541,575 protect, and when does it expire?

Patent 8,541,575 protects BRAFTOVI and is included in one NDA.

This patent has twenty-one patent family members in nineteen countries.

Summary for Patent: 8,541,575
Title:3,4-diarylpyrazoles as protein kinase inhibitors
Abstract: 3,4-diarylpyrazole derivatives of formula (I) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer. ##STR00001##
Inventor(s): Pulici; Maurizio (Caponago, IT), Zuccotto; Fabio (Milan, IT), Badari; Alessandra (Vedano al Lambro, IT), Nuvoloni; Stefano (Genoa, IT), Cervi; Giovanni (Como, IT), Traquandi; Gabriella (Milan, IT), Biondaro; Sonia (Ronca, IT), Trifiro'; Paolo (Genoa, IT), Marchionni; Chiara (Milan, IT), Modugno; Michele (Cernusco sul Naviglio, IT)
Assignee: Nerviano Medical Sciences S.R.L. (Nerviano, IT)
Application Number:13/054,853
Patent Claim Types:
see list of patent claims
Use; Composition; Compound; Device;

Drugs Protected by US Patent 8,541,575

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Array Biopharma Inc BRAFTOVI encorafenib CAPSULE;ORAL 210496-001 Jun 27, 2018 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial Y Y TREATMENT OF MELANOMA ⤷  Try a Trial
Array Biopharma Inc BRAFTOVI encorafenib CAPSULE;ORAL 210496-002 Jun 27, 2018 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y Y TREATMENT OF MELANOMA ⤷  Try a Trial
Array Biopharma Inc BRAFTOVI encorafenib CAPSULE;ORAL 210496-002 Jun 27, 2018 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y Y BRAFTOVI IS A KINASE INHIBITOR INDICATED IN COMBINATION WITH BINIMETINIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH A BRAF V600E OR V600K MUTATION, AS DETECTED BY AN FDA- APPROVED TEST ⤷  Try a Trial
Array Biopharma Inc BRAFTOVI encorafenib CAPSULE;ORAL 210496-002 Jun 27, 2018 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y Y BRAFTOVI IS A KINASE INHIBITOR INDICATED IN COMBINATION WITH CETUXIMAB, FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC COLORECTAL CANCER (CRC) WITH A BRAF V600E MUTATION, AS DETECTED BY AN FDA-APPROVED TEST, AFTER PRIOR THERAPY ⤷  Try a Trial
Array Biopharma Inc BRAFTOVI encorafenib CAPSULE;ORAL 210496-002 Jun 27, 2018 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y Y BRAFTOVI IS A KINASE INHIBITOR INDICATED IN COMBINATION WITH BINIMETINIB, FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON SMALL CELL LUNG CANCER WITH A BRAF V600E MUTATION, AS DETECTED BY AN FDA-APPROVED TEST ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,541,575

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
08161076Jul 24, 2008
PCT Information
PCT FiledJuly 23, 2009PCT Application Number:PCT/EP2009/059506
PCT Publication Date:January 28, 2010PCT Publication Number: WO2010/010154

International Family Members for US Patent 8,541,575

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria E557015 ⤷  Try a Trial
Australia 2009273197 ⤷  Try a Trial
Brazil PI0916356 ⤷  Try a Trial
Canada 2731146 ⤷  Try a Trial
Chile 2011000124 ⤷  Try a Trial
China 102105459 ⤷  Try a Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.